sotagliflozin   Click here for help

GtoPdb Ligand ID: 8312

Synonyms: Inpefa® | LX-4211 | LX4211 | Zynquista®
Approved drug
sotagliflozin is an approved drug (EMA (2019), FDA (2023))
Compound class: Synthetic organic
Comment: Sotagliflozin is a dual inhibitor of the sodium/glucose cotransporters 1 and 2 (SGLT1/2) [5,8]. SGLT1 and SGLT2 mediate glucose reabsorption, by the kidney and in the gastrointestinal tract respectively.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 3
Rotatable bonds 6
Topological polar surface area 104.45
Molecular weight 424.11
XLogP 3.9
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES CCOc1ccc(cc1)Cc1cc(ccc1Cl)C1OC(SC)C(C(C1O)O)O
Isomeric SMILES CCOc1ccc(cc1)Cc1cc(ccc1Cl)[C@@H]1O[C@H](SC)[C@H]([C@@H]([C@H]1O)O)O
InChI InChI=1S/C21H25ClO5S/c1-3-26-15-7-4-12(5-8-15)10-14-11-13(6-9-16(14)22)20-18(24)17(23)19(25)21(27-20)28-2/h4-9,11,17-21,23-25H,3,10H2,1-2H3/t17-,18-,19+,20+,21-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Sotagliflozin received EMA marketing authorisation in April 2019, as a treatment for type I diabetes mellitus in overweight patients for whom insulin alone fails to adequately control blood sugar. It is to be used in combination with insulin therapy to improve glycemic control in these patients. Sotagliflozin was also investigated as an option to treat heart failure [1-2,6-7]. Based on evidence of efficacy in clinical studies, the FDA approved sotagliflozin (in May 2023) to reduce deaths and hospitalisations of patients with heart failure (or at risk of heart failure) with both preserved and reduced left ventricular ejection fraction.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Sotagliflozin combines inhibition of both renal SGLT2 activity with inhibition of intestinal SGLT1 activity. This combined action represents a novel approach to the treatment of diabetes, as current approved drugs of this type (such as dapagliflozin, empagliflozin and canagliflozin) have focussed on selectively inhibiting SGLT2. The dual action appears to provide effective glycemic control with reduced gastrointestinal side effects compared to current SGLT2 inhibitors [8].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03521934 Effect of Sotagliflozin on Cardiovascular Events in Participants With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF Trial) Phase 3 Interventional Lexicon Pharmaceuticals The SOLOIST-WHF trial 4,7
NCT03315143 Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk Phase 3 Interventional Lexicon Pharmaceuticals The SCORED trial 3
External links Click here for help